Today: 18 January 2026
Subscribe
Browse Category

FDA News News 16 December 2025 - 28 December 2025

Altria Stock (MO) News: Dividend Reset, FDA on! PLUS Authorization, and NJOY Legal Battle—What Investors Need Before Monday

Altria Stock (MO) News: Dividend Reset, FDA on! PLUS Authorization, and NJOY Legal Battle—What Investors Need Before Monday

NEW YORK, Dec. 28, 2025, 2:59 PM ET — Market closed Altria Group, Inc. (NYSE: MO) stock heads into the final week of 2025 with investors balancing three key forces: a just-passed ex-dividend reset that can distort short-term price action, a notable regulatory win for its on! PLUS nicotine pouches, and continued legal crosscurrents tied to its NJOY e-vapor business.…
28 December 2025
····
Merck (MRK) Stock Update: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Analyst Targets as Wall Street Heads Into New Year Week

Merck (MRK) Stock Update: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Analyst Targets as Wall Street Heads Into New Year Week

As of 10:40 p.m. ET in New York on Friday, Dec. 26, 2025, U.S. markets have wrapped up the post-Christmas session and are heading into a weekend — leaving investors to digest a fresh cluster of headline catalysts around Merck & Co., Inc. (NYSE: MRK) before the next opening bell. Merck shares finished the regular session around $106.78, after trading…
27 December 2025
····
Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition

Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition

Friday, December 26, 2025, 11:17 a.m. ET in New York. In that context—a quiet, low‑liquidity post‑Christmas session with major U.S. indexes hovering near record highs—Vera Therapeutics, Inc. (Nasdaq: VERA) is trading lower midday. Reuters and the AP both describe today’s market as subdued, with institutions largely “checked out” for year‑end and the broader tape moving only slightly. Reuters As of…
26 December 2025
··
Philip Morris International (PM) in Focus on Dec. 25, 2025: Dividend Deadline, ZYN FDA Catalyst, and 2026 Stock Forecasts

Philip Morris International (PM) in Focus on Dec. 25, 2025: Dividend Deadline, ZYN FDA Catalyst, and 2026 Stock Forecasts

December 25, 2025 — With U.S. markets closed for the Christmas holiday, investor attention has shifted from intraday price moves to the next set of catalysts for Philip Morris International Inc. (NYSE: PM): a dividend deadline arriving tomorrow, an increasingly consequential FDA process around ZYN nicotine pouches, and a growing tug-of-war between “sin stock” discounts and a rapidly expanding smoke-free…
25 December 2025
····
Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum

Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum

December 25, 2025 — Merck & Co., Inc. (NYSE: MRK) is ending 2025 with something investors tend to enjoy: momentum with a story behind it. Even with U.S. markets closed for Christmas Day, Merck shares are in focus after a late-December climb that pushed the stock to fresh highs, helped along by a major Wall Street upgrade and a burst…
25 December 2025
····
Altria (MO) Stock After Hours on Dec. 24, 2025: Dividend Deadline, Unusual Options Surge, and FDA Nicotine Pouch Catalyst Before the Next Market Open

Altria (MO) Stock After Hours on Dec. 24, 2025: Dividend Deadline, Unusual Options Surge, and FDA Nicotine Pouch Catalyst Before the Next Market Open

NEW YORK — December 24, 2025: Altria Group, Inc. (NYSE: MO) ended the holiday-shortened Christmas Eve session modestly higher and then ticked up again in limited after-hours trading, as income-focused investors and options traders honed in on one near-term catalyst that matters most right now: Altria’s next dividend goes ex-dividend on Friday, Dec. 26, 2025. Public Below is what moved…
25 December 2025
····
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is in the spotlight on December 24, 2025 after a sharp selloff driven by a major regulatory development: the U.S. Food and Drug Administration recommended that Reviva run an additional Phase 3 trial for its lead schizophrenia candidate, brilaroxazine, before filing a New Drug Application (NDA). SEC Shares were trading around $0.32 after the…
24 December 2025
····
Abbott Laboratories Stock After Hours (ABT): FDA Win, Holiday Trading Dynamics, and What to Watch Before the Dec. 24 Open

Abbott Laboratories Stock After Hours (ABT): FDA Win, Holiday Trading Dynamics, and What to Watch Before the Dec. 24 Open

Abbott Laboratories (NYSE: ABT) finished Tuesday, Dec. 23, 2025, modestly lower, even as fresh headlines reinforced the company’s medical-device momentum heading into a holiday-shortened U.S. trading session on Wednesday, Dec. 24. ABT shares closed at $124.54 (-0.53%) and in after-hours trading were last indicated around $124.20 (-0.27%) as of the evening session. Yahoo Finance With markets set for an early…
24 December 2025
····
Merck (MRK) Stock After Hours Today (Dec. 23, 2025): Shares Slip Slightly After the Close as Investors Track TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Fresh Wall Street Targets

Merck (MRK) Stock After Hours Today (Dec. 23, 2025): Shares Slip Slightly After the Close as Investors Track TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Fresh Wall Street Targets

NEW YORK — Merck & Co., Inc. (NYSE: MRK) ended regular trading Tuesday, December 23, 2025, at $105.04, and eased modestly in after-hours trading to about $104.81 (down roughly 0.2%) as of early evening in New York. Google The move after the bell was small, but MRK’s two-day run has been anything but: the stock is coming off a sharp…
24 December 2025
····
Intuitive Surgical Stock (ISRG) Week Ahead: FDA da Vinci 5 Recall Posting, da Vinci SP Expansion, and Fresh Wall Street Targets Into the Christmas Trading Week

Intuitive Surgical Stock (ISRG) Week Ahead: FDA da Vinci 5 Recall Posting, da Vinci SP Expansion, and Fresh Wall Street Targets Into the Christmas Trading Week

Date: December 21, 2025 (Sunday) Intuitive Surgical, Inc. (NASDAQ: ISRG) heads into the Christmas-shortened trading week with momentum—yet also with two developments investors will likely keep on the radar: a newly posted FDA Class 2 recall entry tied to a da Vinci 5 console component, and a recent FDA clearance that expands da Vinci SP into three high-volume general surgery…
22 December 2025
····
Altria (MO) Stock in Focus: FDA Clears on! PLUS Nicotine Pouches, Dividend Dates, and the Latest Analyst Forecasts Into 2026

Altria (MO) Stock in Focus: FDA Clears on! PLUS Nicotine Pouches, Dividend Dates, and the Latest Analyst Forecasts Into 2026

Altria Group, Inc. (NYSE: MO) heads into the weekend of December 20, 2025 with investors weighing a rare mix of near-term catalysts: a major U.S. regulatory decision that expands legal “smoke-free” options, a high-yield dividend with a fast-approaching ex-date, and fresh Wall Street updates on valuation and price targets. Shares last closed at $58.07 on Friday, December 19, giving Altria…
21 December 2025
····
Biotech Stocks Today: FDA Fast Track Wins, PDUFA Delays and Deal Flow Move GLUE, ALDX, ADAG, PVLA as XBI and IBB Slide

Biotech Stocks Today: FDA Fast Track Wins, PDUFA Delays and Deal Flow Move GLUE, ALDX, ADAG, PVLA as XBI and IBB Slide

Updated: Tuesday, December 16, 2025 | Early afternoon ET (U.S. stock market) Biotechnology stocks are delivering a classic split-screen session in the U.S. market today: biotech ETFs are slipping, but a handful of single-name biotech movers are swinging sharply on FDA updates, clinical data, and year-end dealmaking. By early afternoon in New York (based on the latest available quotes at the time of…
16 December 2025
···
1 2 3 4 5

Stock Market Today

  • Orion OEC: 26% Rally Fails to Hide Revenue Decline; P/S at 0.2x vs Industry
    January 18, 2026, 9:25 AM EST. Orion S.A. (NYSE: OEC) has jumped 26% in the past month, yet shares remain down about 56% over the last year. The stock trades at a price-to-sales ratio of about 0.2x, well below the industry's roughly 1.1x median. Revenue has declined-4.3% in the last 12 months and 6.7% over three years-underpinning questions about growth. Five analysts project a 0.9% annual decline in revenue over the next three years, versus industry peers forecast to grow about 9.8% annually. The subdued top line explains the low P/S and cautions against extrapolating the rally. Investors will watch for any material revenue improvement that could support a higher multiple. Until then, the P/S may stay under pressure.
Go toTop